{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:41:19Z","timestamp":1792788079083,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T00:00:00Z","timestamp":1660608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Guo-Nan Zhang","award":["2019YFS0036"],"award-info":[{"award-number":["2019YFS0036"]}]},{"name":"Guo-Nan Zhang","award":["2019YFS0036"],"award-info":[{"award-number":["2019YFS0036"]}]},{"name":"Guo-Nan Zhang","award":["2019YFS0036"],"award-info":[{"award-number":["2019YFS0036"]}]},{"name":"Guo-Nan Zhang","award":["2019YFS0036"],"award-info":[{"award-number":["2019YFS0036"]}]},{"name":"Guo-Nan Zhang","award":["2019YFS0036"],"award-info":[{"award-number":["2019YFS0036"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pegylated liposomal doxorubicin (PLD) is a nano-doxorubicin anticancer agent. It was used as early as 2014 to treat ovarian and breast cancer, multiple myeloma and Kaposi's sarcoma. The 2018 National Comprehensive Cancer Network guidelines listed PLD as first-line chemotherapy for ovarian cancer. PLD has significant anticancer efficacy and good tolerance. Although PLD significantly reduces the cardiotoxicity of conventional doxorubicin, its cumulative-dose cardiotoxicity remains a clinical concern. This study summarizes the high-risk factors for PLD-induced cardiotoxicity, clinical dose thresholds, and cardiac function testing modalities. For patients with advanced, refractory, and recurrent malignant tumors, the use of PLD is still one of the most effective strategies in the absence of evidence of high risk such as cardiac dysfunction, and the lifetime treatment dose should be unlimited. Of course, they should also be comprehensively evaluated in combination with the high-risk factors of the patients themselves and indicators of cardiac function. This review can help guide better clinical use of PLD.<\/jats:p>","DOI":"10.1186\/s13048-022-01029-6","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T22:02:36Z","timestamp":1660600956000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer"],"prefix":"10.1186","volume":"15","author":[{"given":"Xin-Ru","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Han","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,16]]},"reference":[{"issue":"2","key":"1029_CR1","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.drudis.2016.11.005","volume":"22","author":"M Cagel","year":"2017","unstructured":"Cagel M, Grotz E, Bernabeu E, Moretton MA, Chiappetta DA. Doxorubicin: nanotechnological overviews from bench to bedside. Drug Discovery Today. 2017;22(2):270\u201381.","journal-title":"Drug Discovery Today"},{"key":"1029_CR2","doi-asserted-by":"crossref","unstructured":"MM. AH Salem HSE, Ghanem E, Abdel-Daim. Mesenchymal Stem Cell Therapy for Doxorubicin-Induced Cardiomyopathy: Potential Mechanisms, Governing Factors, and Implications of the Heart Stem Cell Debate. Front Pharmacol. 2019;10:635.","DOI":"10.3389\/fphar.2019.00635"},{"key":"1029_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.nantod.2019.02.005","volume":"25","author":"J Wolfram","year":"2019","unstructured":"Wolfram J, Ferrari M. Clinical cancer nanomedicine. Nano Today. 2019;25:85\u201398.","journal-title":"Nano Today"},{"issue":"208","key":"1029_CR4","first-page":"120358","volume":"1","author":"J Gao","year":"2020","unstructured":"J. WhZheng M, Gao J, Wang J, Zhang Q, Fawcett JP, He Y, Gu. Uptake and release profiles of PEGylated liposomal doxorubicin nanoparticles: A comprehensive picture based on separate determination of encapsulated and total drug concentrations in tissues of tumor-. Talanta. 2020;1(208):120358.","journal-title":"Talanta"},{"key":"1029_CR5","unstructured":"DOXIL Label. Food and Drug Administration. 2016;"},{"key":"1029_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jconrel.2021.07.006","volume":"337","author":"CN Subasic","year":"2021","unstructured":"Subasic CN, Kuilamu E, Cowin G, Minchin RF, Kaminskas LM. The pharmacokinetics of PEGylated liposomal doxorubicin are not significantly affected by sex in rats or humans, but may be affected by immune dysfunction. J Control Release. 2021;337:71\u201380.","journal-title":"J Control Release"},{"issue":"1","key":"1029_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13048-021-00790-4","volume":"14","author":"XR Li","year":"2021","unstructured":"Li XR, Zhu Y, Zhang GN, Huang JM, Pei. The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials. J Ovarian Res. 2021;14(1):42.","journal-title":"J Ovarian Res."},{"key":"1029_CR8","unstructured":"XL. SS Jiang FF, Hong T, Zhuang Y, Chen L, Huang. Comparison of pegylated liposomal doxorubicin and paclitaxel plus carboplatin-based chemotherapy as first line treatment for patients with ovarian cancer: a systematic review and meta-analysis of rand. Eur Rev Med Pharmacol Sci. 2020;24(6):2911\u201327."},{"issue":"1","key":"1029_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13048-020-00736-2","volume":"14","author":"Z Yuan","year":"2021","unstructured":"Yuan Z, Zhang Y, Cao D, Shen K, Li Q, Zhang G, et al. Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer. J Ovarian Res. 2021;14(1):12.","journal-title":"J Ovarian Res"},{"key":"1029_CR10","doi-asserted-by":"crossref","unstructured":"AA. AD Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, DiBella NJ, Stewart SJ, Kavanagh JJ, Gabizon. Efficacy and safety of liposomal anthracyclines in phase I\/II clinical trials. Semin Oncol. 2004;31(6 Suppl 13):53\u201390.","DOI":"10.1053\/j.seminoncol.2004.08.010"},{"issue":"3","key":"1029_CR11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/CAD.0000000000000182","volume":"26","author":"E Tahover","year":"2015","unstructured":"Tahover E, Patil YP, Gabizon AA. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index. Anticancer Drugs. 2015;26(3):241\u201358.","journal-title":"Anticancer Drugs"},{"issue":"2","key":"1029_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ygyno.2019.09.009","volume":"155","author":"SM Dioun","year":"2019","unstructured":"Dioun SM, Vilardo N, Goldberg GL, Gressel GM. Necessity of routine cardiac evaluation in patients receiving pegylated liposomal doxorubicin for gynecologic cancer. Gynecol Oncol. 2019;155(2):301\u20134.","journal-title":"Gynecol Oncol"},{"key":"1029_CR13","doi-asserted-by":"crossref","unstructured":"G LM Biondi-Zoccai G, Abbate A, Lanzetta G, D\u2019Ascenzo F, Malavasi V, Peruzzi M, Frati. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013;112(12):1980\u20134.","DOI":"10.1016\/j.amjcard.2013.08.026"},{"key":"1029_CR14","doi-asserted-by":"crossref","unstructured":"JM. HD Till C, Shen S, Wright JD, Ramsey SD, Barlow WE, Unger. Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials. J Clin Oncol. 2017;36(26):2710\u20137.","DOI":"10.1200\/JCO.2017.77.4414"},{"key":"1029_CR15","doi-asserted-by":"crossref","unstructured":"MD. BP Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon. Cardiovascular Disease Mortality Among Breast Cancer Survivors. Epidemiology. 2016;27(1):6\u201313.","DOI":"10.1097\/EDE.0000000000000394"},{"issue":"1","key":"1029_CR16","doi-asserted-by":"publisher","first-page":"44877","DOI":"10.1038\/srep44877","volume":"7","author":"H Han","year":"2017","unstructured":"Han H, Guo W, Shi W, Yu Y, Zhang Y, Ye X, et al. Hypertension and breast cancer risk: a systematic review and meta-analysis. Sci Rep. 2017;7(1):44877.","journal-title":"Sci Rep"},{"issue":"3","key":"1029_CR17","doi-asserted-by":"publisher","first-page":"2508","DOI":"10.1021\/acsomega.7b01235","volume":"3","author":"X Wei","year":"2018","unstructured":"Wei X, Shamrakov D, Nudelman S, Peretz-Damari S, Nativ-Roth E, Regev O, et al. Cardinal Role of Intraliposome Doxorubicin-Sulfate Nanorod Crystal in Doxil Properties and Performance. ACS Omega. 2018;3(3):2508\u201317.","journal-title":"ACS Omega"},{"key":"1029_CR18","doi-asserted-by":"crossref","unstructured":"Schilt Y, Berman T, Wei X, Nativ-Roth E, Barenholz Y, Raviv U. Effect of the ammonium salt anion on the structure of doxorubicin complex and PEGylated liposomal doxorubicin nanodrugs. Biochimica et Biophysica Acta (BBA) - General Subjects. 2021;1865(5):129849.","DOI":"10.1016\/j.bbagen.2021.129849"},{"key":"1029_CR19","doi-asserted-by":"crossref","unstructured":"MM. CA Moasser. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008;35(2 Suppl 2):S1\u201314.","DOI":"10.1053\/j.seminoncol.2008.02.010"},{"key":"1029_CR20","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2017.07.010","volume":"261","author":"A F\u00fcredi","year":"2017","unstructured":"F\u00fcredi A, Szeb\u00e9nyi K, T\u00f3th S, Cserepes M, H\u00e1mori L, Nagy V, et al. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. J Control Release. 2017;261:287\u201396.","journal-title":"J Control Release"},{"key":"1029_CR21","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.breast.2016.10.005","volume":"31","author":"M Sundquist","year":"2017","unstructured":"Sundquist M, Brudin L, Tejler G. Improved survival in metastatic breast cancer 1985\u20132016. The Breast. 2017;31:46\u201350.","journal-title":"The Breast"},{"key":"1029_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.breast.2018.03.002","volume":"39","author":"F Cardoso","year":"2018","unstructured":"Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J, et al. Global analysis of advanced\/metastatic breast cancer: Decade report (2005\u20132015). Breast. 2018;39:131\u20138.","journal-title":"Breast"},{"key":"1029_CR23","doi-asserted-by":"crossref","unstructured":"F. LD Sabatucci I, Maltese G, Lepori S, Tripodi E, Bogani G, Raspagliesi. Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis. Tumori. 2019;105(4):282\u2013287.","DOI":"10.1177\/0300891619839308"},{"issue":"1","key":"1029_CR24","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1186\/s12879-019-4500-7","volume":"19","author":"A Ishihara","year":"2019","unstructured":"Ishihara A, Hatakeyama S, Suzuki J, Amano Y, Sasahara T, Toshima M, et al. Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review. BMC Infect Dis. 2019;19(1):848.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"1029_CR25","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/CAD.0000000000000521","volume":"28","author":"A Pendlebury","year":"2017","unstructured":"Pendlebury A, DeBernardo R, Rose PG. Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg\/m2 in recurrent ovarian cancer. Anticancer Drugs. 2017;28(7):815\u20137.","journal-title":"Anticancer Drugs"},{"issue":"7","key":"1029_CR26","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/aogs.12642","volume":"94","author":"A Rabinovich","year":"2015","unstructured":"Rabinovich A, Ramanakumar AV, Lau S, Gotlieb WH. Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study. Acta Obstet Gynecol Scand. 2015;94(7):776\u201380.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"3","key":"1029_CR27","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ygyno.2013.03.012","volume":"129","author":"SE Gill","year":"2013","unstructured":"Gill SE, Savage K, Wysham WZ, Blackhurst DW, Winter WE, Puls LE. Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: Is it necessary? Gynecol Oncol. 2013;129(3):544\u20137.","journal-title":"Gynecol Oncol"},{"key":"1029_CR28","doi-asserted-by":"crossref","unstructured":"S. KJ Odunsi K, Lele. High cumulative doses of pegylated liposomal doxorubicin are not associated with cardiac toxicity in patients with gynecologic malignancies. Chemotherapy. 2010;56(2):108\u201311.","DOI":"10.1159\/000312644"},{"key":"1029_CR29","doi-asserted-by":"crossref","unstructured":"N. PC Misra V, Januszewski A, Yosef H, Ashford R, Keary I, Davidson. Multicenter experience of nonpegylated liposomal doxorubicin use in the management of metastatic breast cancer. Clin Breast Cancer. 2014;14(2):85\u201393.","DOI":"10.1016\/j.clbc.2013.10.011"},{"issue":"4","key":"1029_CR30","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/annonc\/mdl484","volume":"18","author":"E Andreopoulou","year":"2007","unstructured":"Andreopoulou E, Gaiotti D, Kim E, Downey A, Mirchandani D, Hamilton A, et al. Pegylated liposomal doxorubicin HCL (PLD; Caelyx\/Doxil\u00ae): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer. Ann Oncol. 2007;18(4):716\u201321.","journal-title":"Ann Oncol"},{"key":"1029_CR31","doi-asserted-by":"crossref","unstructured":"C; OM Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, Catane R, Kieback DG, Tomczak P, Ackland SP, Orlandi F, Mellars L, Alland L, Tendler. CAELYX Breast Cancer Study Group. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-li. Ann Oncol. 2004;15(3):440\u20139.","DOI":"10.1093\/annonc\/mdh097"},{"issue":"1","key":"1029_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.ygyno.2004.03.024","volume":"94","author":"D Uyar","year":"2004","unstructured":"Uyar D, Kulp B, Peterson G, Zanotti K, Markman M, Belinson J. Cardiac safety profile of prolonged (\u22656 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol Oncol. 2004;94(1):147\u201351.","journal-title":"Gynecol Oncol"},{"key":"1029_CR33","doi-asserted-by":"crossref","unstructured":"E. FS Alsabe H, Djafari L, Janot F, Julieron M, Domenge C, Djazouli K, Armand JP, Luboinski B, Raymond. Locoregional effects of pegylated liposomal doxorubicin (Caelyx) in irradiated area: a phase I-II study in patients with recurrent squamous cell carcinoma of the head and neck. Eur J Cancer. 2004;40(10):1517\u201321.","DOI":"10.1016\/j.ejca.2004.03.018"},{"issue":"3","key":"1029_CR34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ygyno.2015.02.020","volume":"137","author":"CL Kushnir","year":"2015","unstructured":"Kushnir CL, Angarita AM, Havrilesky LJ, Thompson S, Spahlinger D, Sinno AK, et al. Selective cardiac surveillance in patients with gynecologic cancer undergoing treatment with pegylated liposomal doxorubicin (PLD). Gynecol Oncol. 2015;137(3):503\u20137.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"1029_CR35","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s00280-017-3420-8","volume":"80","author":"KM Skubitz","year":"2017","unstructured":"Skubitz KM, Blaes AH, Konety SH, Francis GS. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value. Cancer Chemother Pharmacol. 2017;80(4):787\u201398.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1029_CR36","doi-asserted-by":"crossref","unstructured":"FJ. BG Billingham M, Alderman E, Richardson P, Torti F, Lum B, Patek A, Martin. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi\u2019s sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol. 1998;9(7):711\u20136.","DOI":"10.1023\/A:1008216430806"},{"issue":"5","key":"1029_CR37","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1081\/CNV-200032899","volume":"22","author":"AA Gabizon","year":"2004","unstructured":"Gabizon AA, Lyass O, Berry GJ, Wildgust M. Cardiac Safety of Pegylated Liposomal Doxorubicin (Doxil\u00ae\/Caelyx\u00ae) Demonstrated by Endomyocardial Biopsy in Patients with Advanced Malignancies. Cancer Invest. 2004;22(5):663\u20139.","journal-title":"Cancer Invest"},{"key":"1029_CR38","doi-asserted-by":"crossref","unstructured":"LE. GS Savage K, Wysham WZ, Blackhurst DW, Winter WE, Puls. Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: is it necessary?. Gynecol Oncol. 2013;129(3):544\u20137.","DOI":"10.1016\/j.ygyno.2013.03.012"},{"issue":"1","key":"1029_CR39","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.nano.2013.07.005","volume":"10","author":"RF Schell","year":"2014","unstructured":"Schell RF, Sidone BJ, Caron WP, Walsh MD, White TF, Zamboni BA, et al. Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents. Nanomed Nanotechnol Biol Med. 2014;10(1):109\u201317.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"1029_CR40","doi-asserted-by":"crossref","unstructured":"CM. CG de Azambuja E, Lenihan D, Calabr\u00f2 MG, Cardinale D, Cipolla. Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer. Oncologist. 2019;24(11):e1034\u201343.","DOI":"10.1634\/theoncologist.2018-0773"},{"issue":"1","key":"1029_CR41","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00280-011-1664-2","volume":"69","author":"NM La-Beck","year":"2011","unstructured":"La-Beck NM, Zamboni BA, Gabizon A, Schmeeda H, Amantea M, Gehrig PA, et al. Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemother Pharmacol. 2011;69(1):43\u201350.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1029_CR42","doi-asserted-by":"crossref","unstructured":"HM. GS Ho PJ, Rijnberg N, Emaus MJ, Baak LM, Hartman M, Grobbee DE, Verkooijen. Risk of death from cardiovascular disease following breast cancer: a systematic review. Breast Cancer Res Treat. 2017;164(3):537\u201355.","DOI":"10.1007\/s10549-017-4282-9"},{"issue":"1","key":"1029_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1158\/1078-0432.CCR-07-1033","volume":"14","author":"BRJH Bird","year":"2008","unstructured":"Bird BRJH, Swain SM. Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems. Clin Cancer Res. 2008;14(1):14\u201324.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"1029_CR44","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer. J Clin Oncol. 2007;25(25):3808\u201315.","journal-title":"J Clin Oncol"},{"key":"1029_CR45","doi-asserted-by":"crossref","unstructured":"C. TM Hudis. Cardiac profiles of liposomal anthracyclines: greater cardiac safety versus conventional doxorubicin? Cancer. 2004;100(10):2052\u201363.","DOI":"10.1002\/cncr.20207"},{"key":"1029_CR46","doi-asserted-by":"crossref","unstructured":"Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dub\u00e9 MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR; Canadian Pharmacogenomics Network for Drug Safety Consortium. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012;30(13):1422\u20138.","DOI":"10.1200\/JCO.2010.34.3467"},{"key":"1029_CR47","doi-asserted-by":"crossref","unstructured":"Y. GA Shmeeda H, Barenholz. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003;42(5):419\u201336.","DOI":"10.2165\/00003088-200342050-00002"},{"issue":"3","key":"1029_CR48","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/S1053-4296(03)00037-7","volume":"13","author":"B Oasullivan","year":"2003","unstructured":"Oasullivan B, Levin W. Late radiation-related fibrosis: pathogenesis, manifestations, and current management. Sem Rad Oncol. 2003;13(3):274\u201389.","journal-title":"Sem Rad Oncol"},{"key":"1029_CR49","doi-asserted-by":"crossref","unstructured":"R. DS McGale P, Taylor CW, Peto. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries. Lancet Oncol. 2005;6(8):557\u201365.","DOI":"10.1016\/S1470-2045(05)70251-5"},{"issue":"8","key":"1029_CR50","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1161\/CIR.0000000000000556","volume":"137","author":"LS Mehta","year":"2018","unstructured":"Mehta LS, Watson KE, Barac A, Beckie TM, Bittner V, Cruz-Flores S, et al. Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association. Circulation. 2018;137(8):e30\u201366.","journal-title":"Circulation"},{"issue":"18","key":"1029_CR51","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1161\/CIRCULATIONAHA.114.008820","volume":"130","author":"K Montazeri","year":"2014","unstructured":"Montazeri K, Unitt C, Foody JM, Harris JR, Partridge AH, Moslehi J. ABCDE Steps to Prevent Heart Disease in Breast Cancer Survivors. Circulation. 2014;130(18):e157\u20139.","journal-title":"Circulation"},{"key":"1029_CR52","doi-asserted-by":"crossref","unstructured":"JM WF Breunig F, Beer M, Sandstede J, St\u00f6rk S, Voelker W, Ertl G, Knoll A, Wanner C, Strotmann. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J. 2005;26(12):1221\u20137.","DOI":"10.1093\/eurheartj\/ehi143"},{"issue":"2","key":"1029_CR53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.euje.2005.04.009","volume":"7","author":"S Tassanmangina","year":"2006","unstructured":"Tassanmangina S, Codorean D, Metivier M, Costa B, Himberlin C, Jouannaud C, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: Early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr. 2006;7(2):141\u20136.","journal-title":"Eur J Echocardiogr"},{"key":"1029_CR54","doi-asserted-by":"crossref","unstructured":"JL. BG Mertens L, Di Salvo G, Matthijs I, Weidemann F, Eyskens B, Goossens W, Goemans N, Sutherland GR, Van Hove. Idebenone treatment in Friedreich\u2019s ataxia: neurological, cardiac, and biochemical monitoring. Neurology. 2003;60(10):1679\u201381.","DOI":"10.1212\/01.WNL.0000068549.52812.0F"},{"issue":"15","key":"1029_CR55","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1093\/eurheartj\/ehl013","volume":"27","author":"TG Neilan","year":"2006","unstructured":"Neilan TG. Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. Eur Heart J. 2006;27(15):1868\u201375.","journal-title":"Eur Heart J"},{"issue":"19","key":"1029_CR56","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1161\/01.CIR.0000068313.67758.4F","volume":"107","author":"J Koyama","year":"2003","unstructured":"Koyama J, Ray-Sequin PA, Falk RH. Longitudinal Myocardial Function Assessed by Tissue Velocity, Strain, and Strain Rate Tissue Doppler Echocardiography in Patients With AL (Primary) Cardiac Amyloidosis. Circulation. 2003;107(19):2446\u201352.","journal-title":"Circulation"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-022-01029-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-022-01029-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-022-01029-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T22:03:02Z","timestamp":1660600982000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-022-01029-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1029"],"URL":"https:\/\/doi.org\/10.1186\/s13048-022-01029-6","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,16]]},"assertion":[{"value":"11 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All the authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"96"}}